Nam Q. Bui

Oncology
2589 Samaritan Dr
San Jose, CA 95124

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 79 publications

Reply to: In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors.

Reply to: In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 24, 2026

Pseudomyogenic Hemangioendothelioma Treated with Zoledronic Acid: A Case Report.

Pseudomyogenic Hemangioendothelioma Treated with Zoledronic Acid: A Case Report.

Journal: JBJS case connector
Published: December 18, 2025

A Multicenter Retrospective Outcomes Analysis of Patients with Localized Synovial Sarcoma.

A Multicenter Retrospective Outcomes Analysis of Patients with Localized Synovial Sarcoma.

Journal: Cancer research communications
Published: October 21, 2025

Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial.

Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 20, 2025

A first-in-human, Phase 1/2a, open-label study of SQ3370, a first-in-class doxorubicin-based click chemistry therapeutic, in patients with advanced solid tumors.

A first-in-human, Phase 1/2a, open-label study of SQ3370, a first-in-class doxorubicin-based click chemistry therapeutic, in patients with advanced solid tumors.

Journal: medRxiv : the preprint server for health sciences
Published: June 12, 2025

p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program.

p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program.

Journal: Cancer discovery
Published: March 24, 2025

Gemcitabine Plus Docetaxel, Dacarbazine, Doxorubicin Combinations, or Doxorubicin Alone as First-Line Treatment for Advanced/Metastatic Leiomyosarcoma: A Retrospective Analysis at a Sarcoma Center.

Gemcitabine Plus Docetaxel, Dacarbazine, Doxorubicin Combinations, or Doxorubicin Alone as First-Line Treatment for Advanced/Metastatic Leiomyosarcoma: A Retrospective Analysis at a Sarcoma Center.

Journal: Diseases (Basel, Switzerland)
Published: January 26, 2025

SCAN-ACT: adoptive T cell therapy target discovery through single-cell transcriptomics.

SCAN-ACT: adoptive T cell therapy target discovery through single-cell transcriptomics.

Journal: Genome medicine
Published: January 25, 2025

Musculoskeletal Tumor Care Disparities Prior to Initiation of Treatment Among Newly Diagnosed Adult Patients.

Musculoskeletal Tumor Care Disparities Prior to Initiation of Treatment Among Newly Diagnosed Adult Patients.

Journal: Cancers
Published: January 10, 2025

Histologic and Immunologic Factors Associated with Response to Immune Checkpoint Inhibitors in Advanced Sarcoma.

Histologic and Immunologic Factors Associated with Response to Immune Checkpoint Inhibitors in Advanced Sarcoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 22, 2024

Brain Metastases in Sarcomas: A Multicenter Retrospective Cohort Study.

Brain Metastases in Sarcomas: A Multicenter Retrospective Cohort Study.

Journal: Cancers
Published: October 09, 2024

Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers.

Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers.

Journal: Journal of hematology & oncology
Published: October 08, 2024
Showing 1-12 of 79

Last Updated: 09/26/2026